跳轉至內容
Merck
全部照片(2)

文件

C1277

Sigma-Aldrich

氯硝西泮

powder

同義詞:

5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one

登入查看組織和合約定價
全部照片(2)

About This Item

經驗公式（希爾表示法）:
C15H10ClN3O3
CAS號碼:
1622-61-3
分子量：:
315.71
EC號碼:
216-596-2
MDL號碼:
MFCD00057746
分類程式碼代碼:
12352200
PubChem物質ID:
24892396
NACRES:
NA.77

形狀

powder

藥物控制

USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

顏色

light yellow

起源

Roche

SMILES 字串

Clc1ccccc1C2=NCC(=O)Nc3ccc(cc23)N(=O)=O

InChI

1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

InChI 密鑰

DGBIGWXXNGSACT-UHFFFAOYSA-N

基因資訊

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)
rat ... Tspo(24230)

尋找類似的產品？ 前往 產品比較指南

生化／生理作用

Anticonvulsant; ligand for the GABAA receptor benzodiazepine modulatory site.

特點和優勢

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H336,H412

危險分類

Aquatic Chronic 3 - STOT SE 3

標靶器官

Central nervous system

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 1

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

W Löscher et al.
The Journal of pharmacology and experimental therapeutics, 279(2), 561-572 (1996-11-01)
We have reported recently that the seizure model and experimental protocol may markedly influence anticonvulsant tolerance and withdrawal characteristics of benzodiazepine (BDZ) receptor ligands so that predictions on tolerance and dependence liability of novel drugs should be based on a
Stuart J McCarter et al.
Sleep medicine, 14(3), 237-242 (2013-01-29)
REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin
Raffaele Ferri et al.
Sleep medicine, 14(1), 24-29 (2012-10-27)
To analyze the differences in sleep structure and nocturnal motor activity between drug-free REM sleep behavior disorder (RBD) patients and those under therapy with clonazepam, and to evaluate the long-term longitudinal changes under continued therapy with clonazepam. Fifty-seven consecutive iRBD
G Chouinard
The Journal of clinical psychiatry, 48 Suppl, 29-37 (1987-10-01)
This is a report on the efficacy of clonazepam in the treatment of acute mania. The advantages of clonazepam over standard neuroleptics are its rapidity of action, its lack of toxicity, and, particularly important, the fact that it does not
Ruth Corrigan et al.
The Cochrane database of systematic reviews, 5(5), CD009486-CD009486 (2012-05-18)
Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. Clonazepam, a benzodiazepine, is an established antiepileptic drug, but its place in the treatment of neuropathic pain is unclear.
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務